title: What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
authors.forename: Ulrich
authors.initials: U
authors.lastname: Spandau
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D058452:Axial Length, Eye / Q000033:anatomy & histology; D000068258:Bevacizumab; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D058449:Intravitreal Injections; D015861:Retinal Neovascularization / Q000188:drug therapy; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab